It is an unidarole derivative. Exact machanism of action is not known. Three hypothesis have been proposed.
- Inhibition of DNA synthesis by acting as purine analogue.
- Action as an alkylating agent.
- Interaction with - SH group.
| Composition : | 100mg, 200mg, 500mg |
| Indications : | Metastatic malignant melanoma and as 2nd line drug for hodgkin's disease. |
| Contraindications : | Patient with known hypersensitivity, pregnancy lactation |
| Safety Profile : | Complete blood count should be monitored regularly, oral intake is restricted 4-6 hour prior to the therapy. |
| Adverse Effects : | Haemopoietic depression invading mainly leucocytes and platelets anaphylactoid reaction, anorexia, nausea, vomiting, diarrhoea, influneza like syndrome, alopecia, facial flushing, paresthesia, ash liver function and renal function abnormalities. |
| Dosage : | Malignant melanoma : 2-4.5 mg/kg/day for 10 days may be repeated at 4 weeks intervel or 250 mg/ml of body surface area (BSA)/day for 5 days repeated after 3 weeks. Hodgkin's disease : 150mg/m² to be repeated every 15 days. |
| Purity : | Not less than 99%. |
© Health Biotech Limited. All Rights Reserved (Terms of Use)
